病例报告

双膦酸盐相关性颌骨坏死1例

  • 杨菊 ,
  • 刘玥 ,
  • 曲春娜 ,
  • 孙健斌 ,
  • 李天英 ,
  • 石连杰
展开
  • 1. 遂宁市中心医院风湿免疫科,四川遂宁 629099
    2. 北京大学国际医院风湿免疫科,北京 102206
    3. 北京大学国际医院口腔颌面外科,北京 102206
    4. 北京大学国际医院口腔科,北京 102206
    5. 北京大学国际医院内分泌科,北京 102206
    6. 北京大学国际医院病理科,北京 102206
    7. 北京大学首钢医院风湿免疫科,北京 100144

收稿日期: 2022-04-22

  网络出版日期: 2025-04-12

基金资助

北京大学国际医院院内基金重点项目(YN2020ZD01)

版权

北京大学学报(医学版)编辑部, 2025, 版权所有,未经授权,不得转载。

Bisphosphonates-related osteonecrosis of the jaw: A case report

  • Ju YANG ,
  • Yue LIU ,
  • Chunna QU ,
  • Jianbin SUN ,
  • Tianying LI ,
  • Lianjie SHI
Expand
  • 1. Department of Rheumatology and Immunology, Suining Central Hospital, Suining 629099, Sichuan, China
    2. Department of Rheumatology and Immunology, Peking University International Hospital, Beijing 102206, China
    3. Department of Maxillofacial Surgery, Peking University International Hospital, Beijing 102206, China
    4. Department of Stomatology, Peking University International Hospital, Beijing 102206, China
    5. Department of Endocrinology, Peking University International Hospital, Beijing 102206, China
    6. Department of Pathology, Peking University International Hospital, Beijing 102206, China
    7. Department of Rheumatology and Immunology, Peking University Shougang Hospital, Beijing 100144, China
SHI Lianjie, e-mail, shilianjie1999@163.com

Received date: 2022-04-22

  Online published: 2025-04-12

Supported by

Peking University International Hospital Research Funds(YN2020ZD01)

Copyright

, 2025, All rights reserved. Unauthorized reproduction is prohibited.

本文引用格式

杨菊 , 刘玥 , 曲春娜 , 孙健斌 , 李天英 , 石连杰 . 双膦酸盐相关性颌骨坏死1例[J]. 北京大学学报(医学版), 2025 , 57(2) : 388 -392 . DOI: 10.19723/j.issn.1671-167X.2025.02.026

Abstract

Osteonecrosis of the mandible is also called avascular necrosis of the jaw, and it is a rare complication of bisphosphonates. It is characterized with pain, swelling, exposure of bone, local infection and pathologic fractures of the jaw. With the widespread usage of bisphosphonates in bone metastasis of malignant tumors and osteoporosis, this rare complication has received more attention in recent years. Here, we reported a case of bisphosphonates-related osteonecrosis of the jaw (BRONJ) caused by intravenous zoledronic acid for osteoporosis. A 62-year-old female patient with 7-year history of Sjögren's syndrome and 3-year history of osteoporosis developed BRONJ after 3-year treatment of zoledronic acid. Two months before she went to the Peking University International Hospital, she visited the dentist for periodontal purulent secretion and extracted one tooth from the right mandible. However, the condition was not improved and she felt persistent pain and swelling in the right mandible. Hence, she received repeated root curettage, but there was no improvement. Finally, she was diagnosed with osteonecrosis of the mandible based on the digital volume tomography scan, which showed right mandibular osteonecrosis bone destruction. She underwent surgical debridement of the necrotic bone and administered intravenous antibio-tics at the Peking University International Hospital. Histopathological analysis of the bone biopsy further confirmed the diagnosis of BRONJ. Her condition was improved successfully during a 3-year follow-up. Osteonecrosis of the mandible become more common with the increased use of bisphosphonates. Recent study has reported that osteonecrosis of the mandible is more likely to occur in patients with Sjögren's syndrome. In addition, age, long-term and irregular administration of glucocorticoids, irregular oral examination and treatment also might be the risk factors in the pathogenesis of osteonecrosis of the mandible. For the elder osteoporosis patients who would receive or had received bisphosphonate-related drugs, oral health status and the disease states associated with necrosis of the mandible such as Sjögren's syndrome should be comprehensively measured and fully evaluated during the whole process. Furthermore, to better understand and prevent or reduce the occurrence of this complication, we reviewed the patho-genesis, diagnosis, treatment, and prevention of BRONJ.

参考文献

1 Fleisch H . Biphosphonate as a therapeutic drug: Experimental studies and clinical application[J]. Ther Umsch, 1985, 42 (6): 366- 375.
2 Haraguchi R , Kitazawa R , Mori K , et al. sFRP4-dependent Wnt signal modulation is critical for bone remodeling during postnatal development and age-related bone loss[J]. Sci Rep, 2016, 6, 25198.
3 Marx RE . Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic[J]. J Oral Maxillofac Surg, 2003, 61 (9): 1115- 1117.
4 Everts-Graber J , Lehmann D , Burkard JP , et al. Risk of osteo-necrosis of the jaw under denosumab compared to bisphosphonates in patients with osteoporosis[J]. J Bone Miner Res, 2021, 37 (2): 340- 348.
5 朱洁云, 高敏, 宋秋韵, 等. 中国老年人骨质疏松症患病率的Meta分析[J]. 中国全科医学, 2022, 25 (3): 346- 353.
6 Black DM , Rosen CJ . Clinical practice. Postmenopausal psteoporosis[J]. N Engl J Med, 2016, 374 (3): 254- 262.
7 Kuo PI , Lin TM , Chang YS , et al. Primary Sjogren syndrome increases the risk of bisphosphonate-related osteonecrosis of the jaw[J]. Sci Rep, 2021, 11 (1): 1612.
8 Allen MR , Burr DB . Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment[J]. J Oral Maxillofac Surg, 2008, 66 (5): 987- 994.
9 郎淼杰, 周稚辉, 毛静静, 等. 唑来膦酸对血管内皮细胞损伤的影响[J]. 中华口腔医学杂志, 2015, 50 (7): 399- 402.
10 Taniguchi N , Osaki M , Onuma K , et al. Bisphosphonate-induced reactive oxygen species inhibit proliferation and migration of oral fibroblasts: A pathogenesis of bisphosphonate-related osteonecrosis of the jaw[J]. J Periodontol, 2020, 91 (7): 947- 955.
11 Marx RE , Cillo JE Jr , Ulloa JJ . Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment[J]. J Oral Maxillofac Surg, 2007, 65 (12): 2397- 2410.
12 Koneski F , Popovic-Monevska D , Gjorgoski I , et al. In vivo effects of geranylgeraniol on the development of bisphosphonate-related osteonecrosis of the jaws[J]. J Craniomaxillofac Surg, 2018, 46 (2): 230- 236.
13 Kizub DA , Miao J , Schubert MM , et al. Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307)[J]. Support Care Cancer, 2021, 29 (5): 2509- 2517.
14 Ruggiero SL , Dodson TB , Assael LA , et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw: 2009 update[J]. Aust Endod J, 2009, 35 (3): 119- 130.
15 吴平凡, 李羽, 雷振革, 等. 种植体引起双膦酸盐相关性下颌骨坏死1例[J]. 华西口腔医学杂志, 2020, 38 (4): 460- 463.
16 Adler RA , El-Hajj Fuleihan G , Bauer DC , et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: Report of a task force of the American Society for Bone and Mineral Research[J]. J Bone Miner Res, 2016, 31 (1): 16- 35.
17 He L , Sun X , Liu Z , et al. Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw[J]. Int J Oral Sci, 2020, 12 (1): 30.
18 Yu W , Su J . The effects of different doses of teriparatide on bisphosphonate-related osteonecrosis of the jaw in mice[J]. Oral Dis, 2020, 26 (3): 609- 620.
19 Ruggiero SL , Dodson TB , Fantasia J , et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw: 2014 update[J]. J Oral Maxillofac Surg, 2014, 72 (10): 1938- 1956.
20 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2017)[J]. 中华骨质疏松和骨矿盐疾病杂志, 2017, 10 (5): 413- 443.
21 Watts NB , Diab DL . Long-term use of bisphosphonates in osteoporosis[J]. J Clin Endocrinol Metab, 2010, 95 (4): 1555- 1565.
文章导航

/